Similar articles

• Clairvoyance or reliable prediction of the future?

  van Zandwijk N, van de Vijver MJ. van Zandwijk N, et al. Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503. Ann Oncol. 2007. PMID: 17322538 No abstract available.
• [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].

  Taus Á. Taus Á. Med Clin (Barc). 2016 Apr;146 Suppl 1:30-5. doi: 10.1016/S0025-7753(16)30261-5. Med Clin (Barc). 2016. PMID: 27426246 Review. Spanish.
• Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.

  Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C. Ji Y, et al. JAMA Oncol. 2015 Sep;1(6):838-40. doi: 10.1001/jamaoncol.2015.1300. JAMA Oncol. 2015. PMID: 26181671 No abstract available.
• [Mechanism of action and preclinical development of afatinib].

  Diz Taín P, González AL, García-Palomo A. Diz Taín P, et al. Med Clin (Barc). 2016 Apr;146 Suppl 1:7-11. doi: 10.1016/S0025-7753(16)30257-3. Med Clin (Barc). 2016. PMID: 27426242 Review. Spanish.
• Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.

  Harichand-Herdt S, Ramalingam SS. Harichand-Herdt S, et al. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005. Semin Thorac Cardiovasc Surg. 2008. PMID: 19038731 Review.